Nucleosides for suppressing or reducing the development of resistance in cytostatic therapy

Details for Australian Patent Application No. 2007283729 (hide)

Owner RESprotect GmbH

Inventors Teubner, Janek; Rolfs, Andreas; Heinrich, Jorg-Christian; Fahrig, Rudolf; Dieks, Henrik; Lohmann, Dieter

Agent Griffith Hack

Pub. Number AU-B-2007283729

PCT Pub. Number WO2008/017515

Priority 10 2006 037 786.9 11.08.06 DE

Filing date 13 August 2007

Wipo publication date 14 February 2008

Acceptance publication date 1 September 2011

International Classifications

C07D 405/04 (2006.01) Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom

A61K 31/513 (2006.01) - having oxo groups directly attached to the heterocyclic ring, e.g. cytosine

A61P 35/00 (2006.01) Antineoplastic agents

Event Publications

5 March 2009 PCT application entered the National Phase

  PCT publication WO2008/017515 Priority application(s): WO2008/017515

1 September 2011 Application Accepted

  Published as AU-B-2007283729

12 January 2012 Standard Patent Sealed

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2007283731-Immunogenic peptides and their use in immune disorders

2007283714-Thieno[3,2-c]pyridine-7-carboxylic acid derivatives